Dashboard/BPMC/AYVAKIT/event

ReadoutTopline Readout

AYVAKIT PIONEER 2L GIST Phase 3 Topline

BPMC·AYVAKIT·GIST·

Approved

·NCT04695704

current best date

SEP

2026

MONTH4 months

Takeaway

Phase 3 efficacy readout for AYVAKIT in second-line GIST. AYVAKIT is currently approved in PDGFRA D842V-mutant GIST and indolent/advanced systemic mastocytosis. Watch: PFS vs. sunitinib comparator.

What’s at stake

market · comparables · base rate · prior moves

Market opportunity

—

company filings

Peer comparables

1 readout

ClinicalTrials.gov

Stage base rate

~100%

BIO Industry Analysis 2023 (2011–2020)

Avg prior-readout move

—

historical price reactions

MoAKIT/PDGFRα inhibitor

AYVAKIT (avapritinib) is a highly selective oral kinase inhibitor developed by Blueprint Medicines that targets activating mutations in KIT and PDGFRα — the dominant oncogenic drivers in gastrointestinal stromal tumors (GIST) and systemic mastocytosis. The drug fits precisely into the ATP-binding pocket of these mutant kinases to block the aberrant signaling driving tumor growth and mast cell accumulation. AYVAKIT is approved for PDGFRA Exon 18 D842V-mutant GIST — a subset previously insensitive to imatinib — and for advanced and indolent systemic mastocytosis; Blueprint is studying avapritinib versus sunitinib in second-line GIST in an ongoing Phase 3 trial.

Indication

Oncology - Solid

GIST

MeSH · D046152

No primer in glossary yet.

Trial

active

NCT04695704 ↗

PIONEER Phase 3 Avapritinib in 2L GIST

Glossary · what this readout is measuring

1 term detected in the takeaway

PFSendpoint
Progression-Free Survival
Time from randomization until tumor progression or death. Mid-term oncology endpoint; correlates with overall survival in many tumor types.

Reference data · comparable readouts

How Appr readouts in Oncology - Solid have landed.

Reference, not prediction. We surface the historical record so you can read it yourself. We never extrapolate to the upcoming event.

Positive

0/0

0% in record

Primary endpoint hit

across 0 readouts

Drug · sponsorPhase · yearOutcomeKey metricSource

datopotamab deruxtecan

AZN · NSCLC 2L

Ph3 · Jan 2024mixedPFS hit, OS not stat-sig8-K

tarlatamab

AMGN · SCLC 2L+

Ph2 · Oct 2023positiveORR 40% — first BiTE in SCLCconference

tislelizumab (RATIONALE-303)

BGNE · NSCLC 2L

Ph3 · Apr 2023positiveOS 17.2 vs 11.9 moPR

sotorasib

AMGN · KRAS-G12C NSCLC

Ph3 · Sep 2022mixedPFS hit; OS HR 0.91 (n.s.)conference

enhertu (DESTINY-Breast03)

AZN · HER2+ Breast

Ph3 · Sep 2021positivemPFS 25.1 vs 7.2 moconference

sorted by phase match, then recency · sources span PR wires, CT.gov, FDA notices, and conference presentations · we never editorialize the outcome label

Competitive landscape

1 peer in Oncology - Solid · ranked by indication + modality match

Drug	Company	Modality	Mechanism	Phase	Next catalyst
REC-994	RXRX	small molecule	oxidative stress modulator (CCM)		READOUT · Nov 26

Prior BPMC reactions to Readout events

2 historical events · base rate, not prediction

Median 1W move

+2.5%

Median 1M move

-8.3%

Positive outcomes

0/ 2

Negative outcomes

1/ 2

50%

Date	Headline	Outcome	1W	1M	6M
Jan 2026	AYVAKIT — Phase 3 Topline — Mixed Result	negative	-14.2%	-39.5%	-19.4%
Aug 2024	AYVAKIT — Phase 2b Topline Met Primary Endpoint	mixed	+19.1%	+22.9%	+31.5%

Historical BPMC stock reaction to past Readout catalysts. Past performance is not a forecast — base rates anchor expectations, not outcomes. Positive rate 0%.

Disclosure trail

1 observation · sorted by confidence

Mar 25, 2026·1mo agopinned · highest confidence
HIGH confPR
top claim
SEP2026
MONTH
“PIONEER, the Phase 3 study of AYVAKIT in second-line GIST, is expected to deliver topline data in September 2026.”
conf 89%via llm

MethodologyEvery catalyst date is anchored to a primary source. Disclosures with confidence ≥ 0.85 auto-publish; the rest are reviewed by a human within 24 hours. We never interpret data — we organize public information.